A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-26. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
=== 15 April === Four people were killed by Russian shelling in Siversk, Donetsk Oblast. Two people were killed in a separate attack in Lukiantsi, Kharkiv Oblast. Ukrainian media reported that the Ukrainian military launched a missile attack on a Russian command post in Crimea. The partisan group Atesh claimed that the headquarters of the 810th Marine Brigade in Sevastopol was struck. Ukrainian border guards intercepted a Russian sabotage group trying to enter Sumy Oblast.
=== Precursors to chemicals === By the process of cracking, alkanes can be converted to alkenes. Simple alkenes are precursors to polymers, such as polyethylene and polypropylene. When the cracking is taken to extremes, alkanes can be converted to carbon black, which is a significant tire component. Chlorination of methane gives chloromethanes, which are used as solvents and building blocks for complex compounds. Similarly treatment of methane with sulfur gives carbon disulfide. Still other chemicals are prepared by reaction with sulfur trioxide and nitric oxide.
== Wear == The effect of wear on a roller chain is to increase the pitch (spacing of the links), causing the chain to grow longer. Note that this is due to wear at the pivoting pins and bushes, not from actual stretching of the metal (as does happen to some flexible steel components such as the hand-brake cable of a motor vehicle). With modern chains it is unusual for a chain (other than that of a bicycle) to wear until it breaks, since a worn chain leads to the rapid onset of wear on the teeth of the sprockets, with ultimate failure being the loss of all the teeth on the sprocket. The sprockets (in particular the smaller of the two) suffer a grinding motion that puts a characteristic hook shape into the driven face of the teeth. (This effect is made worse by a chain improperly tensioned, but is unavoidable no matter what care is taken). The worn teeth (and chain) no longer provides smooth transmission of power and this may become evident from the noise, the vibration or (in car engines using a timing chain) the variation in ignition timing seen with a timing light. Both sprockets and chain should be replaced in these cases, since a new chain on worn sprockets will not last long. However, in less severe cases it may be possible to save the larger of the two sprockets, since it is always the smaller one that suffers the most wear. Only in very light-weight applications such as a bicycle, or in extreme cases of improper tension, will the chain normally jump off the sprockets. The lengthening due to wear of a chain is calculated by the following formula:
=== Ryan York === Ryan York (Matt Lauria) is a young soldier who develops a relationship with Amber. In early season four Ryan meets Zeek at a VA support group and they eventually become good friends. Later, Ryan meets Amber, Zeek's granddaughter, and the two strike up a friendship. The two are instantly attracted to each other, which the rest of the Braverman family notices. Eventually, Amber and Ryan begin dating and are happy. Amber notices that he can be a little violent and impulsive, but she ignores those who say that Ryan is troubled from his time in war. However, near the end of Season 4, Ryan is called back to his base, and he and Amber say goodbye. In the Season 5 premiere, Ryan comes home to Amber and upon seeing her, decides to spontaneously propose. She accepts, and the two begin planning their wedding. They reveal the news to Amber's mother, Sarah, who does not like the idea at first but warms up to it gradually. Initially, Ryan suggests that they just get married at a courthouse, but they ultimately decide that they will get married in front of Amber's family by the lake. When Amber and Sarah question why Ryan's family won't be attending the wedding, he lies and says that they won't be able to make it. However, it is later discovered that his relationship with his mother is strained, and his father is dead. After Amber begins working at the Luncheonette with the band, Ashes of Rome, she spends more time there than with Ryan. He feels that she is very distant and not really with him anymore.
Sources: en.wikipedia.org
FSO3F + 2 KI → KSO3F + KF + I2 Fluorine fluorosulfate reacts with SSF2, SeF4, AsF3, and MoF5 and also with SF4, Br2, and I2. All compounds react exothermically, and sometimes explosively, between 80–298 K.
=== Cardiovascular system === Meta-analyses have reported a reduced risk of death from ischemic heart disease and from cerebrovascular disease among vegetarians. A 2023 systematic review and meta-analysis of prospective cohort studies found that vegetarian diets were associated with a reduced risk of cardiovascular disease overall and of ischemic heart disease in particular, while evidence for stroke was less clear.
Pizza Hut also offers a chicken wing menu. The menu was launched in 2003 under the WingStreet branding in existing Pizza Hut franchises, with the plan to turn WingStreet into a standalone chain. Yum! Brands predicted aggressive growth, adding more than 4,000 locations by 2010. In 2012, the company opened a standalone pilot store in Denton, Texas. The store was unsuccessful and closed the following year.
Sources: en.wikipedia.org
Counter-Strike: Source has been played in tournaments since shortly after its release. However, the game received criticism from parts of the competitive community, who felt that it was not sufficiently refined for high-level competitive play and that its skill ceiling was significantly lower than that of Counter-Strike 1.6. One common criticism concerned the altered recoil patterns of automatic weapons, which were more random than in the original game and were viewed by many players as reducing the importance of mechanical skill. Another major point of contention was the reduction in bullet penetration through walls, while grenade explosions could no longer inflict damage through solid surfaces. Changes to grenade mechanics were also criticized by some players for altering established strategies from previous versions of the game. Players additionally pointed to shortcomings in the game's lag compensation system, which could cause discrepancies between player models and their hitboxes. The game's significantly higher hardware requirements compared to Counter-Strike 1.6 also proved to be a barrier for some competitive players and organizations, particularly during the early years following its release. This caused a divide in the competitive community as to which game to play competitively.
Saroglitazar (INN, trade names Lipaglyn, Bilypsa) is a drug for the treatment of type 2 diabetes mellitus, dyslipidemia, NASH and NAFLD It is approved for use in India by the Drug Controller General of India. Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol, VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a characteristic hallmark of atherogenic diabetic dyslipidemia (ADD). It has also shown anti-diabetic medication properties by reducing the fasting plasma glucose and HBA1c in diabetes patients.
== Mechanism == EAAT1 functions in vivo as a homotrimer. EAAT1 mediates the transport of glutamic and aspartic acid with the cotransport of three Na+ and one H+ cations and counter transport of one K+ cation. This co-transport coupling (or symport) allows the transport of glutamate into cells against a concentration gradient.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.